Pediatric Hematology/Oncology

Journal Club ft. Nature Publications   

Questions discussed in this category



Are there specific safety concerns or long-term risks that should be accounted for when considering drug holidays or overall treatment duration?

How will you implement response assessments in patients starting tovorafenib given potential for pseudoprogression vs true progression?

Is it merely another option to try or will it become the standard choice for patients experiencing relapsed/refractory disease?


Papers discussed in this category


Nature medicine, 2023 Nov 17